Temsirolimus (CCI-779)in Newly Diagnosed Glioblastoma

• Research type

  Research Study

• Full title

  Radiation therapy and concurrent plus adjuvantTemsirolimus (CCI-779) versus chemo-irradiation with temozolomide in newly diagnosed glioblastoma withoutmethylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study.

• IRAS ID

  33874

• Contact name

  Susan Short

• Sponsor organisation

  EORTC Headquarters

• Eudract number

  2008-003003-31

• ISRCTN Number

  not known

• Research summary

  This research study is aiming to develop a novel treatment for a type of brain tumour (glioblastoma).The study drug, temsirolimus, (Temsirolimus, sirolimus 42-ester with 2, 2-bis (hydroxymethyl) propionic-acid) blocks cell growth. Inhibition of the activity of the target protein mTOR (mammalian target of rapamycin) prevents cells producing key proteins regulating tumour gene expression, cell growth, new blood vessel formation and nutrient transport into the cell.

• REC name

  London - West London & GTAC Research Ethics Committee

• REC reference

  10/H0803/149

• Date of REC Opinion

  4 Mar 2011

• REC opinion

  Further Information Favourable Opinion